REG - GSK PLC - Update on phase I/II therapeutic HSV vaccine trial

GSKAnnouncement

11/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240911:nRSK6634Da&default-theme=true

RNS Number : 6634D  GSK PLC  11 September 2024

Issued: 11 September 2024, London UK

 

GSK provides update on phase I/II therapeutic herpes simplex virus (HSV)
vaccine trial

 

 

 

GSK plc (LSE/NYSE: GSK) today announced that it has completed the primary
objective data analysis from the phase II part of the TH HSV REC-003 trial.
This trial is a combined phase I/II proof-of-concept study to assess potential
clinical efficacy of GSK3943104, an early-stage therapeutic herpes simplex
virus (HSV) vaccine candidate, before progressing it for further clinical
development.

 

Results show that GSK3943104 did not meet the study's primary efficacy
objective. This vaccine candidate, therefore, will not progress to phase III
studies. No safety concern was observed. The TH HSV REC-003 study will
continue for routine safety monitoring and to generate follow-up data that
could offer valuable insights into recurrent genital herpes. GSK is working
closely with investigators to inform trial participants.

 

Given the unmet medical need and burden associated with genital herpes,
innovation in this area is still needed. GSK intends to evaluate the totality
of all these data and other studies to progress future research and
development of its HSV programme.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Simon Moore        +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Alison Hunt        +1 540 742 3391       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q2 Results for 2024.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESZZGMLZGRGDZZ